Welcome to eviQ
A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.
Find out more
The United Kingdom Chemotherapy Board has published Good Practice Guideline for Immuno-Oncology Medicines.
These guidelines are designed to give a practical framework for the safe introduction and ongoing use of immunotherapy in existing Systemic Anti-Cancer Therapy (SACT) services.
The eviQ and eviQ Education teams are currently recruiting three content author positions. Click the link to find out details.
A NEW template has been published allowing for a single protocol with multiple indications. The first example is ID 3555 metastatic nivolumab for melanoma, NSCLC and RCC.
Following the 1st August 2018 expanded PBS listing for pegfilgrastim to include primary prophylaxis for patients with >20% risk of FN, eviQ is reviewing all impacted protocols. Further information of protocol updates will follow.